Indivior PLC (NASDAQ:INDV) Short Interest Update

Indivior PLC (NASDAQ:INDV) saw a significant growth in short interest in July. As of July 15th, there was short interest totalling 601,700 shares, a growth of 532.0% from the June 30th total of 95,200 shares. Currently, 0.5% of the shares of the stock are sold short. Based on an average daily volume of 320,700 shares, the days-to-cover ratio is currently 1.9 days.

Indivior Price Performance

Shares of INDV traded down $0.30 on Friday, hitting $12.79. The company’s stock had a trading volume of 1,487,673 shares, compared to its average volume of 920,827. The company has a market capitalization of $1.76 billion, a PE ratio of 1,279.00 and a beta of 0.69. The company has a debt-to-equity ratio of 23.50, a current ratio of 0.92 and a quick ratio of 0.74. Indivior has a fifty-two week low of $9.14 and a fifty-two week high of $24.11. The company has a 50 day moving average price of $15.09 and a 200 day moving average price of $17.64.

Indivior (NASDAQ:INDV) last announced its earnings results on Thursday, April 25th. The company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.01). The business had revenue of $284.00 million during the quarter, compared to analyst estimates of $300.00 million. Indivior had a negative return on equity of 4,735.71% and a negative net margin of 12.29%. On average, research analysts anticipate that Indivior will post 1.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

INDV has been the topic of a number of recent research reports. Craig Hallum decreased their price objective on Indivior from $37.00 to $24.00 and set a “buy” rating on the stock in a report on Wednesday, July 10th. Piper Sandler initiated coverage on Indivior in a report on Tuesday. They set an “overweight” rating and a $22.00 price objective on the stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Indivior by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 5,899,190 shares of the company’s stock worth $90,081,000 after buying an additional 52,836 shares in the last quarter. Norges Bank bought a new stake in shares of Indivior during the 4th quarter valued at $36,011,000. Toronto Dominion Bank raised its position in shares of Indivior by 58.0% during the 1st quarter. Toronto Dominion Bank now owns 2,094,865 shares of the company’s stock valued at $44,872,000 after acquiring an additional 769,000 shares during the last quarter. Premier Fund Managers Ltd raised its position in shares of Indivior by 17.8% during the 4th quarter. Premier Fund Managers Ltd now owns 850,980 shares of the company’s stock valued at $12,901,000 after acquiring an additional 128,611 shares during the last quarter. Finally, UBS Group AG increased its position in shares of Indivior by 71.9% in the 4th quarter. UBS Group AG now owns 826,130 shares of the company’s stock valued at $12,615,000 after buying an additional 345,556 shares in the last quarter. 60.33% of the stock is owned by institutional investors and hedge funds.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.